Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average recommendation of “Moderate Buy” by the eighteen ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $27.1111.

A number of analysts have recently weighed in on the stock. HC Wainwright reduced their target price on shares of Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wedbush reissued a “neutral” rating and set a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th. Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 6th. Guggenheim reissued a “buy” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Wednesday, August 13th. Finally, Royal Bank Of Canada decreased their price target on Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Friday, August 8th.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares of the company’s stock, valued at $1,486,989.24. This represents a 6.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the purchase, the director owned 134,693 shares of the company’s stock, valued at $1,350,970.79. The trade was a 288.24% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 12,534 shares of company stock worth $153,837. Insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Ensign Peak Advisors Inc raised its position in Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after purchasing an additional 1,100 shares in the last quarter. Benjamin Edwards Inc. lifted its stake in shares of Intellia Therapeutics by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after purchasing an additional 1,126 shares during the last quarter. HighTower Advisors LLC boosted its position in Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock valued at $120,000 after purchasing an additional 1,282 shares in the last quarter. Johnson Financial Group Inc. grew its stake in Intellia Therapeutics by 24.8% in the second quarter. Johnson Financial Group Inc. now owns 6,988 shares of the company’s stock valued at $66,000 after purchasing an additional 1,388 shares during the last quarter. Finally, Harbour Investments Inc. raised its holdings in Intellia Therapeutics by 27.2% in the second quarter. Harbour Investments Inc. now owns 6,633 shares of the company’s stock worth $62,000 after purchasing an additional 1,419 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $12.27 on Friday. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -2.62 and a beta of 2.28. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $23.76. The business’s 50 day simple moving average is $11.67 and its 200-day simple moving average is $9.63.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million for the quarter, compared to analysts’ expectations of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. Intellia Therapeutics’s quarterly revenue was up 104.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.52) earnings per share. On average, sell-side analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.